Shamburg News · 8-K filed Nov 16, 2026, 4:07 PM EST
LeonaBio Reports Third Quarter 2026 Financial Results and Business Update
LONA · LeonaBio, Inc.
- Earnings
- Other event
- Materiality: high
LeonaBio, Inc. reported a net loss of $21.2 million, or $0.89 per share, for the quarter ended September 30, 2026, compared with a net loss of $6.6 million, or $1.68 per share, for the prior-year quarter. Research and development expenses were $14.6 million and general and administrative expenses were $6.9 million for the quarter, with the increase attributed mainly to ELAINE-3 Phase 3 trial spend. Cash, cash equivalents and investments were $32.3 million as of September 30, 2026, and the company said it expects to enroll ELAINE-3 in the fourth quarter of 2026 with topline data expected in the second half of 2027.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001193125-26-463483.
Written from the filing by Shamburg Markets. Figures are as reported by the company.